Filing Details

Accession Number:
0000950170-24-026098
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-05 16:39:07
Reporting Period:
2024-03-03
Accepted Time:
2024-03-05 16:39:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
818686 Teva Pharmaceutical Industries Ltd TEVA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1995297 L Vikki Conway C/O Teva Pharmaceutical Industries Ltd.
124 Dvora Hanevi'A St.,
Tel Aviv L3 6944020
See "Remarks" No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2024-03-03 5,179 $0.00 8,107 No 4 M Direct
Ordinary Shares Disposition 2024-03-04 1,490 $13.37 6,617 No 4 S Direct
Ordinary Shares Acquisiton 2024-03-04 7,117 $0.00 13,734 No 4 M Direct
Ordinary Shares Disposition 2024-03-04 2,042 $13.37 11,692 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Restricted Share Units Disposition 2024-03-03 5,179 $0.00 5,179 $0.00
Ordinary Shares Restricted Share Units Disposition 2024-03-04 7,117 $0.00 7,117 $0.00
Ordinary Shares Restricted Share Units Acquisiton 2024-03-04 33,482 $0.00 33,482 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
15,538 No 4 M Direct
14,237 No 4 M Direct
33,482 No 4 A Direct
Footnotes
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023.
  4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  6. Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027.
  7. Restricted share units were granted on March 4, 2022, with 7,117 vesting on each of March 4, 2024 and March 4, 2025, and 7,120 vesting on March 4, 2026.
  8. Restricted share units were granted on March 4, 2024, with 8,370 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 8,372 vesting on March 4, 2028.